"Thanks you for not recommending"
There is a vast difference between:
1. Stating my favorable opinion about the efficacy and potential of Sucanon based on publicly available studies,while pointing out that,as a practitioner in the USA, it is not my role to recommend or prescribe Sucanon when it is not FDA approved for sale in the USA.
2. Your statement that I don't recommend (Sucanon)
That misstatement is known as a false dilemma. I, of course, am not in charge of other countries approval process for pharmaceutical sales or the process in the US. I can and do say based on my experience that preclinical results where Sucanon outperformed sulfonylureas and biguanides in animal testing with a therapeutic index of >10,000; randomized double blinded placebo controlled study in 370 adults, 6 months where Sucanon outperformed Glyburide, and a follow up 12 week study in 97 prediabetics that showed normalization of HbA1C in 81% of subjects presented at EASD annual meeting 2013, are all very impressive results which bode well for the future clinical success of Sucanon provided that it can be successfully marketed and those results communicated.
As any can see the above is a far cry from " not recommending"
It is however, recognizing that my recommendation means very little without being backed up by publicly verifiable information supported by cold hard science. I encourage any however, to do DD and look up the studies and judge for themselves the significance. The science doesn't change and can be reproduced and verified. My statements or other claims on this board can be "fact checked", a challenge which I thoroughly welcome.
